Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4066/AMJ.2015.2441 http://scihub22266oqcxt.onion/10.4066/AMJ.2015.2441 C4560895!4560895!26392822     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Australas+Med+J 2015 ; 8 (8): 253-62 Nephropedia Template TP {{tp|p=26392822|t=2015. Cadazolid: A new hope in the treatment of Clostridium difficile infection |pdf=|usr=}}{{26392822}} gab.com Text Cadazolid: A new hope in the treatment of Clostridium difficile infection JO: Australas Med J http://www.kidney.de/pget.php?&tw=1&pmid=26392822 #FOAvip Clostridium difficile infection (CDI) is a potential life-threatening consequence of antibiotic therapy. Although the risk increases with duration of treatment, it can also occur after a short treatment course. In addition to broad-spectrum antibiotics, anti-neoplastic agents, proton pump inhibitors, H2 blockers, and several other drugs have been reported to induce intestinal dysbiosis, which is central to the pathogenesis of CDI. There is an increase in incidence and mortality attributed to CDI globally. Moreover, the epidemiology of C. difficile-associated diseases has changed significantly with an increasing occurrence of community-acquired CDI. Metronidazole and oral vancomycin are the first-line antibiotics used to treat CDI. However, metronidazole has limited effectiveness in severe cases and vancomycin use is associated with increasing risk of vancomycin resistance among Enterococcus spp. Cadazolid, a novel oxazolidinone antibiotic, has recently shown potent antimicrobial activity against C. difficile and has a lower propensity to induce resistance. The implications of its use in treating CDI have been reviewed based on current evidence. Twit Text FOAVip Cadazolid: A new hope in the treatment of Clostridium difficile infection ????Australas Med J http://www.kidney.de/pget.php?&tw=1&pmid=26392822 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26392822 #FOAvip English Wikipedia <ref>{{Cite pmid|26392822}}</ref> Cadazolid: A new hope in the treatment of Clostridium difficile infection #MMPMID26392822 Kali A; Charles MVP; Srirangaraj S Australas Med J 2015[]; 8 (8): 253-62 PMID26392822show ga Clostridium difficile infection (CDI) is a potential life-threatening consequence of antibiotic therapy. Although the risk increases with duration of treatment, it can also occur after a short treatment course. In addition to broad-spectrum antibiotics, anti-neoplastic agents, proton pump inhibitors, H2 blockers, and several other drugs have been reported to induce intestinal dysbiosis, which is central to the pathogenesis of CDI. There is an increase in incidence and mortality attributed to CDI globally. Moreover, the epidemiology of C. difficile-associated diseases has changed significantly with an increasing occurrence of community-acquired CDI. Metronidazole and oral vancomycin are the first-line antibiotics used to treat CDI. However, metronidazole has limited effectiveness in severe cases and vancomycin use is associated with increasing risk of vancomycin resistance among Enterococcus spp. Cadazolid, a novel oxazolidinone antibiotic, has recently shown potent antimicrobial activity against C. difficile and has a lower propensity to induce resistance. The implications of its use in treating CDI have been reviewed based on current evidence. äCadazolid: A new hope in the treatment of Clostridium difficile infect(epmc).pdf DeepDyve Pubget Overpricing